Abstract
ABSTRACT Objectives: Though highly vulnerable to HIV and STIs, transgender female sex workers (TFSW) are understudied in the U.S. HIV and STI response. This study examined the correlates of laboratory-confirmed STIs among a cohort of 62 TFSW followed over the course of one year and explored associations between specimen site and self-reported engagement in insertive and receptive anal intercourse. Methods: Participants completed an interviewer-administered computer assisted personal interview at baseline, 3-, 6-, 9-, and 12-month visits where self-administered anal swabs and urine samples for gonorrhea, chlamydia, and trichomonas were also collected. HIV testing was conducted at baseline, 6-, and 12-month visits. Results: Baseline HIV prevalence was 40.3% with no HIV seroconversions over follow-up. Baseline prevalence of gonorrhea, chlamydia, and trichomonas was 9.7%, 17.7%, and 14.5%, respectively. In the multivariable regression modeling, recent arrest was significantly associated with testing positive for any STI (aRR 1.77; 95% CI: 1.10-2.84). Insertive anal sex with clients was associated with increased risk of testing positive for an STI via urine specimen (RR 3.48; 95% CI: 1.14-10.62), while receptive anal sex was not significantly associated with specimen site. Conclusion: Our findings confirm a high prevalence of STIs among TFSW and highlight the importance of addressing structural drivers such as criminal justice involvement as well as the need to ensure screening for STIs at all anatomical sites regardless of self-reported sites of potential exposure. More research is needed to better understand HIV and STI vulnerabilities and appropriate interventions for TFSW in the U.S.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Drug Abuse (R01DA038499-01) and Johns Hopkins University Center for AIDS Research (1P30AI094189). Tonia Poteat was supported by Johns Hopkins Institute for Clinical and Translational Research (KL2TR001077-05). Ju Nyeong Park was supported by a Faculty Development Grant from the Johns Hopkins University Center for AIDS Research. Sean T. Allen was supported by the National Institutes of Health (K01DA046234). Jennifer L. Glick was supported by NIH/NIDA (T32DA007292). Charlotte Gaydos was supported by the National Institute of Biomedical Imaging and Bioengineering (U54007958) and the National Institute of Allergy and Infectious Diseases (U01068613). The funders had no role in study design, data collection, or in analysis and interpretation of the results, and this paper does not necessarily reflect views or opinions of the funders.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified participant data are available from Dr. Susan Sherman at Johns Hopkins University: https://orcid.org/0000-0001-8399-7544 upon reasonable request and review after submission of a manuscript concept form.
